Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 949-958

  Bu, He Qi ^a   Luo, Jiang ^a   Chen, Hui ^a   Zhang, Jian Hong ^a   Li, Hong Hai ^a   Guo, Hong Chun ^a   Wang, Zhao Hong ^a   Lin, Sheng Zhang ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Gemcitabine; Oridonin; p38; p53; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE P38; ORIDONIN; PROTEIN P53; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DITERPENES, KAURANE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, NUDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANCREATIC NEOPLASMS; RANDOM ALLOCATION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865044204     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1519     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2008. Toronto, ISSN 0835-2976, 2008.
3. Reske SN: PET and PET-CT of malignant tumors of the exocrine pancreas. Radiologe 49: 131-136, 2009 (In German).
4. Stathis A and Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172, 2010.
5. American Cancer Society: Cancer Facts and Figures 2007 [M]. American Cancer Society, New York, NY, 51-52, 2007.
6. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
7. O'Reilly EM and Abou-Alfa GK: Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 34: 347-353, 2007. (Pubitemid 47176624)
8. O'Reilly EM: Pancreatic adenocarcinoma: new strategies for success. Gastrointest Cancer Res 3: S11-S15, 2009.
9. Tingstedt B, Johansson P, Andersson B and Andersson R: Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response. Scand J Gastroenterol 42: 754-759, 2007. (Pubitemid 46763583)
10. Kang SP and Saif MW: Optimal second-line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data? J Oral Pathol 9: 83-90, 2008. (Pubitemid 351611723)
11. Kunnumakkara AB, Guha S, Krishnan S, et al: Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res 67: 3853-3861, 2007. (Pubitemid 46762173)
12. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S and Aggarwal BB: Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127: 257-268, 2010.
13. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM: Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res 69: 5575-5583, 2009.
14. Wang ZH, Chen H, Guo HC, Tong HF, Liu JX, Wei WT, Tan W, Ni ZL, Liu HB and Lin SZ: Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int J Oncol 39: 1123-1131, 2011.
15. Chen H, Wei W, Guo Y, Liu A, Tong H, Wang Z, Tan W, Liu J and Lin S: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25: 1253-1261, 2011.
16. Wei WI, Chen H, Ni ZL, Liu HI, Tong HF, Fan L, Liu A, Qiu MU, Liu DL, Guo HC, Wang ZH and Lin SZ: Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation. Int J Oncol 39: 1381-1390, 2011.
17. Sun HD, Huang SX and Han QB: Diterpenoids from isodon species and their biological activities. Nat Prod Rep 23: 673-698, 2006.
18. Huang J, Wu L, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 107: 370-379, 2008.
19. Jin S, Shen JN, Wang J, Huang G and Zhou JG: Oridonin induced apoptosis through AKT and MAPKS signaling pathways in human osteosarcoma cells. Cancer Biol Ther 6: 261-268, 2007. (Pubitemid 46641633)
20. Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S and Ikejima T: Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull 29: 1873-1879, 2006. (Pubitemid 44338410)
21. Li D, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin induced A431 cell apoptosis partially through blockage of the RAS/RAF/ERK signal pathway. J Pharmacol Sci 103: 56-66, 2007. (Pubitemid 46175595)
22. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffler HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23: 1187-1193, 2003.
23. Hu HZ, Yang YB, Xu XD, Shen HW, Shu YM, Ren Z, Li XM, Shen HM and Zeng HT: Oridonin induces apoptosis via PI3K/Akt pathway in cervical carcinoma HeLa cell line. Acta Pharmacol Sin 28: 1819-1826, 2007. (Pubitemid 350029332)
24. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005. (Pubitemid 41393783)
25. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S and Ikejima T: Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-RAS-RAFJNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 490: 70-75, 2009.
26. Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, Zhao YZ, Fang Y, Chen FY and Wu YL: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 10: 610, 2010.
27. Rufini A and Melino G: Cell death pathology: The war against cancer. Biochem Biophys Res Commun 414: 445-450, 2011.
28. Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405, 2010.
29. Martelli AM, Nyåkern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C and Cocco L: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 20: 911-928, 2006. (Pubitemid 43797279)
30. Wu GS: The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 3: 156-161, 2004.
31. McCubrey JA, Lahair MM and Franklin RA: Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8: 1775-1789, 2006. (Pubitemid 44726351)
32. Kholodenko BN and Birtwistle MR: Four-dimensional dynamics of MAPK information processing systems. Wiley Interdiscip Rev Syst Biol Med 1: 28-44, 2009.
33. Rodríguez-Berriguete G, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R and Royuela M: MAP kinases and prostate cancer. J Signal Transduct 2012: 169170, 2012.
34. Wada T and Penninger JM: Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23: 2838-2849, 2004. (Pubitemid 38638846)
35. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005. (Pubitemid 40638098)
36. Shi Y, Sahu RP and Srivastava SK: Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer 8: 294, 2008.
37. Ma Y, Yu WD, Kong RX, Trump DL and Johnson CS: Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathway in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Cancer Res 66: 8131-8138, 2006. (Pubitemid 44299180)
38. Filomeni G, Graziani I, Rotilio G and Ciriolo MR: trans-Resveratrol induces apoptosis in human breast cancer cells MCF-7 by the activation of MAP kinases pathways. Genes Nutr 2: 295-305, 2007.
39. Bulavin DV and Fornace AJ Jr: p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92: 95-118, 2004. (Pubitemid 39458114)
40. Vousden KH and Prives C: P53 and prognosis: new insights and further complexity. Cell 120: 7-10, 2005. (Pubitemid 40094596)
41. Galluzzi L, Morselli E, Kepp O, Tajeddine N and Kroemer G: Targeting p53 to mitochondria for cancer therapy. Cell Cycle 7: 1949-1955, 2008. (Pubitemid 352030339)
42. Califice S, Waltregny D, Castronovo V and van den BrÛle F: Prostate carcinoma cell lines and apoptosis: a review. Rev Med Liege 59: 704-710, 2004 (In French).
43. Kim YS, Lee HJ, Jang C, Kim HS and Cho YJ: Knockdown of RCAN1.4 increases susceptibility to FAS-mediated and DNA damage-induced apoptosis by upregulation of p53 expression. Korean J Physiol Pharmacol 13: 483-489, 2009.